Virtual roundtable organised by the EAASM
With the new EU Pharmaceutical Strategy, it is the right time to set the scene for building a pan-European consensus so that regulatory support and enhancements in the field of nanomedicines can be developed further and thus provide medicines with the highest quality, safety and efficacy profiles to European patients. This of course applies to existing medicines but the plethora of new medicines that are in the pipeline.
The virtual event will bring together high-level speakers from the European Parliament, the European Commission, the European Medicines Agency, academia and EU health stakeholders with the view to discuss current challenges and provide useful recommendations to address unmet medical needs and enhance quality, safety and efficacy of nanomedicines and nanosimilars by addressing patient safety issues due to significant regulatory challenges across Europe.